Sisunatovir is an orally administered fusion inhibitor designed to block RSV replication by inhibiting F-mediated fusion with the host cell.
Respiratory syncytial virus (RSV) is a respiratory pathogen that can lead to severe and life-threatening acute lower respiratory tract infection (ALRTI) in populations with weakened immune systems, including young children and the elderly. ALRTI is a leading cause of global childhood morbidity and mortality. In China, RSV is the most common viral pathogen associated with ALRTI.
In China, RSV-associated ALRTI is estimated to affect more than 3.3 million pediatric and elderly patients annually, including more than 400,000 patients who require hospitalization each year.
Development plans: LianBio plans to develop sisunatovir in China initially for the treatment of pediatric patients, as part of ReViral’s global clinical development program.